PTK2 and cancer: Apart from the MET/FAK axis, which we mechanistically explore in our work, the screen yielded other hits without known links to MET and/or FAK signalling, including ontology noted previously for synergistic interaction with catalytic inhibition of CDK4/6, such as RPS6KA6 and BRAF, inhibitors of which increase the response of cancer cells to CDK4/6 inhibition [2, 21, 41].